Group 1 - The company has signed a restructuring investment agreement with several investors, marking a significant progress in its pre-restructuring process [2][3] - The total share capital will increase from 350 million shares to 876 million shares, with a capital reserve conversion ratio of 10 shares to 15 shares, at a conversion price of 2.42 yuan per share [3] - The pre-restructuring process was initiated by the Shiyan Intermediate People's Court on January 20, 2025, appointing a temporary manager for the company [3][4] Group 2 - The restructuring investment agreement indicates potential improvements in the company's financial structure and debt resolution if the restructuring process is successful [4] - However, there are risks associated with the inability of investors to fulfill their funding obligations as per the agreement [4] - The company is currently facing a high risk of delisting due to negative net assets and continuous losses over three years [5][6] Group 3 - The company reported a net loss of 628 million yuan for 2024, with non-recurring net profits also negative for three consecutive years [6][7] - The company is involved in 117 ongoing lawsuits with a total amount of 1.731 billion yuan, and has significant overdue debts totaling 747 million yuan [6] - Financial difficulties are compounded by asset freezes and forced executions due to creditor lawsuits, impacting the company's operations [6][7]
*ST长药预重整迎实质性进展 仍面临较高退市风险
Zheng Quan Ri Bao·2025-05-07 12:39